ZIM Laboratories Gets Australia Nod for Migraine Treatment

ZIM Laboratories Limited announced that its Australian subsidiary, ZIMTAS, received Marketing Authorization from the Therapeutic Goods Administration (TGA) for Rizatriptan Benzoate Orally Disintegrating Films. This marks ZIM's first Marketing Authorization in Australia, facilitating commercial launch via ZIMTAS. The approval validates ZIM's oral thin film platform and is expected to springboard additional regulatory filings in the Asia-Pacific region.